Non-Small-Cell Lung Carcinoma Clinical Trials

14 recruitingLast updated: June 17, 2026

There are 14 actively recruiting non-small-cell lung carcinoma clinical trials across 35 countries. Studies span Phase 1, Phase 2, Phase 3, Not Applicable. Top locations include Houston, Texas, United States, Barcelona, Spain, Frankfurt am Main, Hesse, Germany. Updated daily from ClinicalTrials.gov.


Non-Small-Cell Lung Carcinoma Trials at a Glance

14 actively recruiting trials for non-small-cell lung carcinoma are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Houston, Barcelona, and Frankfurt am Main. Lead sponsors running non-small-cell lung carcinoma studies include Pfizer, AstraZeneca, and Allist Pharmaceuticals, Inc..

Browse non-small-cell lung carcinoma trials by phase

Treatments under study

About Non-Small-Cell Lung Carcinoma Clinical Trials

Looking for clinical trials for Non-Small-Cell Lung Carcinoma? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-Small-Cell Lung Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-Small-Cell Lung Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1Phase 2

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled102 locationsNCT06772623
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorEsophageal Squamous Cell Carcinoma+7 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals44 enrolled10 locationsNCT05703516
Recruiting

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
AstraZeneca600 enrolled29 locationsNCT06494540
Recruiting
Not Applicable

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

ALK+ Non-Small-Cell Lung Carcinoma
Pfizer90 enrolled31 locationsNCT06487078
Recruiting

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNSCLC+6 more
GFPC Investigation100 enrolled16 locationsNCT07563205
Recruiting
Phase 3

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled305 locationsNCT07144280
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1Phase 2

Retifanlimab and Ruxolitinib In Solid Malignancies

Renal Cell CarcinomaNon-Small-Cell Lung Carcinoma
University of California, San Diego40 enrolled1 locationNCT07219576
Recruiting
Phase 1Phase 2

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Carcinoma
AstraZeneca210 enrolled48 locationsNCT04995523
Recruiting
Phase 3

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Non-Small-Cell Lung Carcinoma
Allist Pharmaceuticals, Inc.318 enrolled1 locationNCT04853342
Recruiting
Phase 2

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

Non-Small-Cell Lung CarcinomaEGFR Gene MutationAdvanced Non-Small Cell Squamous Lung Cancer
The Netherlands Cancer Institute16 enrolled1 locationNCT06222489
Recruiting

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

Triple-Negative Breast CancerRenal Cell CarcinomaNon-Small-Cell Lung Carcinoma+1 more
VastBiome800 enrolled1 locationNCT05037825